About VLife Sciences Technologies
VLife Sciences Technologies is a company based in Pune (India) founded in 2002. VLife Sciences Technologies has raised $300.38 thousand across 1 funding round from investors including Keepital. VLife Sciences Technologies offers products and services including VLifeMDS, QSARpro, and BioPredicta. VLife Sciences Technologies operates in a competitive market with competitors including Insitro, Certara, HotSpot Therapeutics, CytoReason and GRO Biosciences, among others.
- Headquarter Pune, India
- Stage Minicorn
- SectorsHealthcare
- Website vlifesciences.com
- Social LinkedIn
- Legal Name Vlife Sciences Technologies Private Limited
- Date of Incorporation 25 Sep, 2002
- Jurisdiction Pune, Maharashtra, India
- Total Equity Funding$300.38K (USD)
in 1 rounds
- Latest Funding Round$300.38K (USD), Seed
Nov 2011
- Investors
Associated legal entities of VLife Sciences Technologies
VLife Sciences Technologies is associated with 2 registered companies on The Company Check; the primary company is Vlife Sciences Technologies Private Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Vlife Sciences Technologies Private Limited CIN U74210PN2002PTC017313 | Amalgamated | 25 Sep 2002 | Pune, Maharashtra | – | – | 4 | View details |
| Novalead Pharma Private Limited CIN U73100PN2007PTC130929 | Active | 31 Oct 2007 | Pune, Maharashtra | ₹0.2 Cr | – | 6 | View details |
Products & Services of VLife Sciences Technologies
VLife Sciences Technologies offers a comprehensive portfolio of products and services, including VLifeMDS, QSARpro, and BioPredicta.
Software for molecular dynamics simulations in drug discovery.
Tool for quantitative structure-activity relationship analysis and optimization.
Platform for biological predictions and lead optimization in research.
Funding Insights of VLife Sciences Technologies
VLife Sciences Technologies has successfully raised a total of $300.38K through 1 strategic funding round. The most recent funding activity was a Seed round of $300.38 thousand completed in November 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $300,380
- Total Rounds 1
- Last Round Seed — $300,380
- First Round $300,380
(Nov 2011)
- Investors Count 1
All 1 funding rounds of VLife Sciences Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2011 | $300,380 | Seed | $1.87M | Keepital | – |
| Date | Valuation | Stage |
|---|---|---|
| Nov 2011 | $1.87M | •••••••• |
Last known valuation $1.87M (Nov 2011). 1 investors in total: 1 institutional.
Investors in VLife Sciences Technologies
VLife Sciences Technologies has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Keepital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Online B2B marketplace for business listings, supplier connections, and product showcases. | 2013 | keepital.com | Singapore, Singapore |
Investor details for VLife Sciences Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Vlife Sciences Technologies Private Limited (VLife Sciences Technologies)
Vlife Sciences Technologies Private Limited is the primary company behind VLife Sciences Technologies. The boards of the 2 registered companies of VLife Sciences Technologies currently have 8 directors; the longest-serving is Atul Sharad Aslekar, appointed in 2007. 13 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Atul Sharad Aslekar DIN 00126698 | Director | 31 Oct 2007 | 18 yrs 11 mo | Novalead Pharma Private Limited, Vlife Sciences Technologies Private Limited |
| Supreet Deshpande Kiran DIN 00126671 | Director | 31 Oct 2007 | 18 yrs 11 mo | Novalead Pharma Private Limited, Vlife Sciences Technologies Private Limited |
| Sudhir Kulkarni Appaji DIN 02768943 | Director | 17 Aug 2009 | 17 yrs 1 mo | Novalead Pharma Private Limited |
| Girish Vithalrao Lakhe DIN 00335011 | Director | 17 Aug 2009 | 17 yrs 1 mo | Novalead Pharma Private Limited |
| Lal Lokumal Chellaram DIN 01579571 | Nominee Director | 05 Nov 2011 | 14 yrs 11 mo | Vlife Sciences Technologies Private Limited |
| Himanshu Nivsarkar DIN 06452428 | Additional Director | 17 Dec 2012 | 13 yrs 9 mo | Vlife Sciences Technologies Private Limited |
| Sankara Narayanan Sankarasubramanian DIN 03543495 | Nominee Director | 24 Nov 2022 | 3 yrs 10 mo | Novalead Pharma Private Limited |
| Vandan Girdharlal Agrawal DIN 00041252 | Nominee Director | 24 Nov 2022 | 3 yrs 10 mo | Novalead Pharma Private Limited |
Timeline of VLife Sciences Technologies
3 dated milestones of VLife Sciences Technologies across 9 years, from founding to its latest funding, stage changes and deals.
- Founded VLife Sciences Technologies is founded.
- Funding First funding round of $300K.
- Milestone Reaches Minicorn status.
Competitors of VLife Sciences Technologies
VLife Sciences Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, Certara, HotSpot Therapeutics, CytoReason and GRO Biosciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| certara.com | 2008 | Princeton, United States | – | 827 | Provider of a platform for in silico drug discovery and consulting services | |
| hotspotthera.com | 2017 | Boston, United States | $210M | 37 | Developer of a platform for protein function analysis | |
| cytoreason.com | 2016 | Haifa, Israel | $100M | – | Immune system-based drugs are discovered via biological data analytics. | |
| grobio.com | 2016 | Boston, United States | $91.15M | 22 | Synthetic biology tools are developed via genetic code recoding techniques. | |
| tolremo.com | 2017 | Zurich, Switzerland | $55.81M | – | Anti-cancer small molecules are developed to target drug resistance pathways. | |
| inpharmatica.co.uk | 1998 | London, United Kingdom | – | 62 | Developer of predictive informatics based platform for drug discovery | |
| recludixpharma.com | 2020 | San Diego, United States | $60M | 33 | Provider of the online platform for drug discovery and development | |
| postera.ai | 2019 | London, United Kingdom | $26.2M | 3 | AI based molecular designing software for drug discovery | |
| cartography.bio | 2020 | Foster, United States | $124M | 10 | Provider of a platform to discover immunotherapeutics |
Detailed competitors of VLife Sciences Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of VLife Sciences Technologies
Websites that share an audience with VLife Sciences Technologies (vlifesciences.com).
Websites whose visitors overlap most with VLife Sciences Technologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biomolecular-modeling.com | 100% | – | #10,993,863 | View details | |
vina.scripps.edu | vina.scripps.edu | 97% | – | – | – |
| testden.com | 70% | – | #585,092 | View details | |
| ninesigma.com | 70% | 12.1K | #1,948,191 | View details | |
| nalmco.org | 70% | – | #5,694,030 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for VLife Sciences Technologies
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Similar companies to VLife Sciences Technologies
10 companies that operate in the same segment as VLife Sciences Technologies (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about VLife Sciences Technologies
VLife Sciences Technologies was founded in 2002 and raised its 1st funding round 9 years after it was founded.
VLife Sciences Technologies is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.
VLife Sciences Technologies is a funded company, having raised a total of $300.38K across 1 funding round to date. The company's 1st funding round was a Seed of $300.38K, raised on Nov 2011.
Founded in 2002 in Pune, India, the company operates in the biopharmaceutical sector. A fully integrated suite of solutions for ligand-based and structure-based rational drug design is offered. Add-on software tools are available for integration with existing research setups. Additionally, research, knowledge, and technology services are provided to biopharma companies and research institutions through a dedicated service arm.
VLife Sciences Technologies's top competitors include Insitro, HotSpot Therapeutics and Certara.
VLife Sciences Technologies offers VLifeMDS, QSARpro, and BioPredicta.
VLife Sciences Technologies has 1 investor. Key investors include Keepital.
The valuation of VLife Sciences Technologies is $1.87M as of Nov 2011.
VLife Sciences Technologies is associated with 2 legal entities: Vlife Sciences Technologies Private Limited, Novalead Pharma Private Limited.
The legal entities of VLife Sciences Technologies currently have 8 directors, including Sankara Narayanan Sankarasubramanian, Sudhir Kulkarni Appaji, Vandan Girdharlal Agrawal and others.